title: Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
abstract: OBJECTIVE
  To evaluate 25 hydroxyvitamin D (25-OH-D) deficiency in a cohort ofpredialysis CKD patients and the treatment effect and safety of high dose ergocalciferol supplement in predialysis CKD.
  
  
  METHODS
  Fifty-six predialysis CKD patients who came for a regular visit at a single hospital with calculated glomerular filtration rate < or =60 mL/min/1.73 m2 were screened for 25-OH-D levels. Forty-four patients with 25-OH-D deficiency were recruited into this prospective observational study that examined the effect of high dose oral ergocalciferol supplementation. After eight weeks, 37 patients completed the follow-up and biochemical parameters were reevaluated and analyzed.
  
  
  RESULTS
  The mean 25-OH-D level of 56 patients was 25.6 +/- 8 ng/mL. Forty-four (78.5%) patients had 25-OH-D levels less than 30 ng/mL and four (7.1%) had severe deficiency with the level less than 15 ng/mL. High dose ergocalciferol supplement successively increased 25-OH-D levels in 35 (95%) patients. 25-OH-D levels increased significantly from 22 +/- 4.8 to 34.5 +/- 10.8 ng/mL after eight weeks (p < 0.001). During the study period, there were no changes in serum calcium, phosphate, and PTH. There was no other side effect associated with the treatment.
  
  
  CONCLUSIONS
  25-OH-D deficiency were found in this cohort of predialysis CKD patients. Ergocalciferol was a safe and effective supplement for the 25-OH-D in predialysis CKD.
authors: Division of Nephrology, Department ofMedicine, BMA Medical college and Vajira Hospital, Bangkok, Thailand. thananda@hotmail.com
authors: Thananda
authors: T
authors: Trakarnvanich
authors: Oran
authors: O
authors: Chalapipat
authors: Sinee
authors: S
authors: Disthabanchong
authors: Sathit
authors: S
authors: Kurathong
authors: Kearkiat
authors: K
authors: Praditpornsilpa
authors: Wasana
authors: W
authors: Stitchantrakul
authors: La-Or
authors: LO
authors: Chailurkit
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects*; D016896:Treatment Outcome; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014815:Vitamins / Q000627:therapeutic use*
chemical_list: D004872:Ergocalciferols; D010281:Parathyroid Hormone; D014815:Vitamins; D010758:Phosphorus; D002118:Calcium